The effect of anagliptin on blood glucose and serum lipids in Patients with type 2 diabetes mellitus
Not Applicable
- Conditions
- Type 2 diabetes mellitus
- Registration Number
- JPRN-UMIN000030532
- Lead Sponsor
- Japan Community Health care Organization, Yokohama Hodogaya Central Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
1. Allergy for anagliptin. 2. Severe ketosis, diabetic coma severe infection, before operation, severe trauma 3. Severe renal dysfunction including hemodialysis or peritoneal dialysis (SCr:more than 1.5mg/dl ) 4. Pregnancy 5. Patients judged by the investigator to be ineligible for some other reason
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change of HbA1c and lipid levels(LDL-C,MDA-LDL,RLP-C)
- Secondary Outcome Measures
Name Time Method 1. Change of HbA1c and lipid levels 2. The change of glycemic and lipid parameters 3. The analysis of baseline characteristics 4. The analysis of backgorund factors which affect glycemic and lipid control